Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-21T00:13:37.925Z Has data issue: false hasContentIssue false

Chapter 36 - HPV-associated Dysplasia of Skin and Mucosa and Vaccination Options in Trans People

from Section G - Screening and Prophylaxis

Published online by Cambridge University Press:  22 December 2022

By
Sophie Pils  and
Elmar Joura
Edited by
Mick van Trotsenburg ,
Rixt A. C. Luikenaar  and
Maria Cristina Meriggiola
Mick van Trotsenburg
Affiliation:
Sigmund Freud PrivatUniversität, Wien
Rixt A. C. Luikenaar
Affiliation:
Rebirth Health Center, Utah
Maria Cristina Meriggiola
Affiliation:
Università di Bologna
Get access

Summary

Human papilloma viruses (HPV) are responsible for various diseases. At least 80% of all people become infected with HPV during their lifetime. The most common transmission route is sexual contact and intense skin contact; less than 1% of all infections occur during birth via vertical transmission.

Type
Chapter
Information
Context, Principles and Practice of TransGynecology
Managing Transgender Patients in ObGyn Practice
 , pp. 267 - 270
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bosch, FX, Broker, TR, Forman, D, et al. Comprehensive control of HPV infections and related diseases. Vaccine 2013;31(8):11–31.CrossRefGoogle ScholarPubMed
Doerfler, D, Bernhaus, A, Kottmel, A, et al. Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol 2009;200(5):487.e1–5.Google Scholar
Giuliano, AR, Lee, JH, Fulp, W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011;377(9769):932–940.CrossRefGoogle ScholarPubMed
Loverro, G, Di Naro, E, Caringella, AM, et al. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect 2016;92(1):67–69.CrossRefGoogle Scholar
Reisner, SL, Deutsch, MB, Peitzmeier, SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One 2018;13(3):e0190172.Google Scholar
Cranston, RD, Carballo-Diéguez, A, Gundacker, H, et al. Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. Int J STD AIDS 2019;30(2):154–162.CrossRefGoogle ScholarPubMed
van der Sluis, WB, Buncamper, ME, Bouman, MB, et al. Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands. Sex Transm Dis 2016;43(8):503–505.CrossRefGoogle ScholarPubMed
Koutsky, LA, Ault, KA, Wheeler, CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645–1651.Google Scholar
Pils, S, Joura, EA. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015;21(9):827–833.Google Scholar
Garland, SM, Hernandez-Avila, M, Wheeler, CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928–1943.Google Scholar
Joura, EA, Leodolter, S, Hernandez-Avila, M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369(9574):1693–1702.Google Scholar
Palefsky, JM, Giuliano, AR, Goldstone, S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576–1585.CrossRefGoogle ScholarPubMed
Chaturvedi, AK, Graubard, BI, Broutian, T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol 2018;36(3):262–267.CrossRefGoogle ScholarPubMed
Joura, EA, Giuliano, AR, Iversen, OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711–723.Google Scholar
Huh, WK, Joura, EA, Giuliano, AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 2017;390(10108):2143–2159.CrossRefGoogle Scholar
Drolet, M, Bénard, É, Pérez, N, Brisson, M, HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394(10197):497–509.CrossRefGoogle ScholarPubMed
Castellsagué, X, Muñoz, N, Pitisuttithum, P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011;105(1):28–37.Google Scholar
Van Damme, P, Meijer, CJ, Kieninger, D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 2016;34(35):4205–4212.CrossRefGoogle ScholarPubMed
Joura, EA, Garland, SM, Paavonen, J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.Google Scholar
Jentschke, M, Kampers, J, Becker, J, Sibbertsen, P, Hillemanns, P. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine 2020;38(41):6402–6409.Google Scholar
Ghelardi, A, Marrai, R, Bogani, G, et al. Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease. Vaccines (Basel) 2021;9(2):83.Google Scholar
Hartwig, S, Baldauf, JJ, Dominiak-Felden, G, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res 2015;1:90–100.Google Scholar
Garland, SM, Steben, M, Sings, HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199(6):805–814.Google Scholar
Lacey, CJ, Woodhall, SC, Wikstrom, A, Ross, J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013;27(3):e263–270.Google Scholar
Matsuki, S, Kusatake, K, Hein, KZ, Anraku, K, Morita, E. Condylomata acuminata in the neovagina after male-to-female reassignment treated with CO2 laser and imiquimod. Int J STD AIDS 2015;26(7):509–511.CrossRefGoogle ScholarPubMed
Labanca, T, Mañero, I. Vulvar condylomatosis after sex reassignment surgery in a male-to-female transsexual: complete response to imiquimod cream. Gynecol Oncol Rep 2017;20:75–77.Google Scholar
Blomberg, M, Friis, S, Munk, C, Bautz, A, Kjaer, S. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012;205(10):1544–1553.Google Scholar
US Preventive Services Task Force, Curry, SJ, Krist, AH, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA 2018;320(7):674–686.Google Scholar
Committee Opinion No. 512: Health Care for Transgender Individuals. Obstet Gynecol 2011;118(6):1454–1458.Google Scholar
Rollston, Rebekah. Promoting cervical cancer screening among female-to-male transmasculine patients. The Fenway Institute, 2019. Available at: https://fenwayhealth.org/wp-content/uploads/TFIP-28_TransMenCervicalCancerScreeningBrief_web.pdfGoogle Scholar
McDowell, M, Pardee, DJ, Peitzmeier, S, et al. Cervical cancer screening preferences among trans-masculine individuals: patient-collected human papillomavirus vaginal swabs versus provider-administered pap tests. LGBT Health 2017;4(4):252–259.Google Scholar
Peitzmeier, SM, Khullar, K, Reisner, SL, Potter, J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med 2014;47(6):808–812.Google Scholar
Peitzmeier, SM, Reisner, SL, Harigopal, P, Potter, J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med 2014;29(5):778–784.Google Scholar
Schenck, TL, Holzbach, T, Zantl, N, et al. Vaginal carcinoma in a female-to-male transsexual. J Sex Med 2010;7(8):2899–2902.CrossRefGoogle Scholar
Harder, Y, Erni, D, Banic, A. Squamous cell carcinoma of the penile skin in a neovagina 20 years after male-to-female reassignment. Case Rep Br J Plast Surg 2002;55(5):449–451.CrossRefGoogle Scholar
Bollo, J, Balla, A, Rodriguez Luppi, C, et al. HPV-related squamous cell carcinoma in a neovagina after male-to-female gender confirmation surgery. Int J STD AIDS 2018;29(3):306–308.Google Scholar
Fernandes, HM, Manolitsas, TP, Jobling, TW. Carcinoma of the neovagina after male-to-female reassignment. J Low Genit Tract Dis 2014;18(2):E43–45.CrossRefGoogle ScholarPubMed
Fierz, R, Ghisu, GP, Fink, D. Squamous carcinoma of the neovagina after male-to-female reconstruction surgery: a case report and review of the literature. Case Rep Obstet Gynecol 2019;2019:4820396.Google ScholarPubMed
Wang, G, Ferguson, D, Ionescu, DN, et al. HPV-related neovaginal squamous cell carcinoma presenting as lung metastasis after male-to-female gender confirmation surgery. Case Rep Oncol 2020;13(1):17–22.Google Scholar
Urban, RR, Teng, NN, Kapp, DS. Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance. Am J Obstet Gynecol 2011;204(5):e9–e12.Google Scholar
Driák, D, Samudovský, M. Could a man be affected with carcinoma of cervix? The first case of cervical carcinoma in trans-sexual person (FtM): case report. Acta Medica (Hradec Kralove) 2005;48(1):53–55.Google Scholar
van der Sluis, WB, Buncamper, ME, Bouman, MB, et al. Symptomatic HPV-related neovaginal lesions in transgender women: case series and review of literature. Sex Transm Infect 2016;92(7):499–501.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×